Division of Research and Innovation, Akershus University Hospital, Lørenskog, Norway.
Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Clin Chem. 2021 Jun 1;67(6):889-898. doi: 10.1093/clinchem/hvab030.
MicroRNA (miR)-210 expression is induced by acute and chronic hypoxia and provides prognostic information in patients with aortic stenosis and acute coronary syndrome. We hypothesized that circulating miR-210 concentrations could provide diagnostic and prognostic information in patients with acute heart failure (HF).
We measured miR-210 concentrations in serum samples on admission from 314 patients hospitalized for acute dyspnea and 9 healthy control subjects. The diagnostic and prognostic properties of miR-210 were tested in patients after adjudication of all diagnoses and with median follow-up of 464 days.
All patients and control subjects had miR-210 concentrations within the range of detection, and the analytical variation was low as the coefficient of variation of synthetic spike-in RNA was 4%. Circulating miR-210 concentrations were increased in patients with HF compared to healthy control subjects, but miR-210 concentrations did not separate patients with acute HF (n = 143) from patients with non-HF-related dyspnea (n = 171): the area under the curve was 0.50 (95% CI 0.43-0.57). Circulating miR-210 concentrations were associated with mortality (n = 114) after adjustment for clinical risk factors (hazard ratio 1.65 [95% CI 1.03-2.62] per unit miR-210 increase), but this association was attenuated and not significant after adjustment for established cardiac protein biomarkers.
Circulating miR-210 concentrations are associated with mortality, but do not add to established protein biomarkers for diagnosis or prognosis in patients with acute dyspnea.
微小 RNA(miR)-210 的表达受急性和慢性缺氧诱导,并为主动脉瓣狭窄和急性冠状动脉综合征患者提供预后信息。我们假设循环 miR-210 浓度可在急性心力衰竭(HF)患者中提供诊断和预后信息。
我们测量了 314 名因急性呼吸困难住院的患者和 9 名健康对照者入院时血清样本中的 miR-210 浓度。在排除所有诊断并中位随访 464 天后,对患者进行了 miR-210 的诊断和预后特性测试。
所有患者和对照者的 miR-210 浓度均在检测范围内,且分析变异度低,合成的 RNA 内参 RNA 的变异系数为 4%。与健康对照者相比,HF 患者的循环 miR-210 浓度升高,但 miR-210 浓度不能将急性 HF 患者(n=143)与非 HF 相关呼吸困难患者(n=171)区分开来:曲线下面积为 0.50(95%CI 0.43-0.57)。在调整临床危险因素后,循环 miR-210 浓度与死亡率相关(n=114,每增加 1 个 miR-210 单位,风险比为 1.65 [95%CI 1.03-2.62]),但在调整既定心脏蛋白生物标志物后,这种相关性减弱且不显著。
循环 miR-210 浓度与死亡率相关,但不能增加急性呼吸困难患者的既定蛋白生物标志物用于诊断或预后。